作者:Júlio Menezes、Luana Vaz、Paula de Abreu Vieira、Kátia da Silva Fonseca、Cláudia Carneiro、Jason Taylor
DOI:10.3390/molecules20010043
日期:——
Chagas disease is a so-called “neglected disease” and endemic to Latin America. Nifurtimox and benznidazole are drugs that have considerable efficacy in the treatment of the acute phase of the disease but cause many significant side effects. Furthermore, in the Chronic Phase its efficiency is reduced and their therapeutic effectiveness is dependent on the type of T. cruzi strain. For this reason, the present work aims to drive basic research towards the discovery of new chemical entities to treat Chagas disease. Differently substituted 5,7-diaryl-2,3-dihydro-1,4-diazepines were synthesized by cyclocondensation of substituted flavones with ethylenediamine and tested as anti-Trypanosoma cruzi candidates. Epimastigotes of the Y strain from T. cruzi were used in this study and the number of parasites was determined in a Neubauer chamber. The most potent diaryldiazepine that reduced epimastigote proliferation exhibited an IC50 value of 0.25 μM, which is significantly more active than benznidazole.
恰加斯病被称为“被忽视的疾病”,在拉丁美洲是地方性流行病。尼夫替莫司和苯达莫司是对该病急性期治疗效果显著的药物,但会产生许多显著的副作用。此外,在慢性期它们的疗效下降,且治疗效果依赖于T. cruzi菌株的类型。因此,本研究旨在推动基础研究,发现新的化学实体来治疗恰加斯病。通过将取代的黄酮与乙二胺进行环缩合,合成了不同取代的5,7-二芳基-2,3-二氢-1,4-二氮杂平,并作为抗克氏锥虫候选药物进行测试。本研究使用了来自T. cruzi Y株的滋养体,并在新宝尔计数室中测定了寄生虫的数量。表现出抑制滋养体增殖的最强效二芳基二氮杂平,其IC50值为0.25 μM,显著高于苯达莫司。